Among patients using GLP-1 medications, 61% were reported to experience midface volume loss, followed by skin laxity (50%) and facial wrinkles or folds (35%)
Several expert sources emphasize prioritizing adequate protein and adding strength training to help maintain lean mass
The study design included sequential rounds of a three-day vehicle-treated baseline phase, a three-day treatment phase, and a two-to-three-day washout phase
Among amino acid transporters genes (SLC families: 1, 3, 6, 7, 15, 16, 25, 36, 38, and 43) 78 , many genes in the SLC6 and SLC7 families, exhibited elevated expression following EV39 treatment in preterm organoids (Supplementary Fig
Its engineered structure allows it to activate both GIP and GLP-1 receptors, making it a dual incretin receptor agonist rather than a GLP-1-only medication